The medical foods for inborn errors of metabolism market was valued at US$ 2,507.80 million in 2019 and it is projected to reach US$ 5,768.79 million in 2027; it is expected to grow at a CAGR of 11.2% from 2020 to 2027.
Medical food refers to the specialized kind of food formulated to be consumed under physician supervision and intended for specific dietary management of a particular disease or condition. These medical conditions usually have distinctive nutritional requirements based on scientific and recognized principles that are established by medical evaluation. The medical food differs from drugs; however they are intended for consumption under the medical supervision as a primary intervention. When infants are identified with inborn errors of metabolism, they are usually prescribed a special diet suitable to their particular condition that must be followed for the lifetime. The growth of the global medical foods for inborn errors of metabolism market is attributed to the increasing incidence of inborn errors of metabolism and increasing preference towards dietary food supplements. However, limitations associated to medical foods for inborn errors of metabolism is the major factor hindering the market growth.
The global medical foods for inborn errors of metabolism market is expected to witness substantial growth post-pandemic. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide. However, the medical technologies and imaging segment is witnessing drop in sales due to a smaller number of surgeries being carried out and delayed or prolonged equipment procurement. Additionally, virtual consultations by healthcare professionals are expected to become the mainstream care delivery model post-pandemic. With telehealth transforming care delivery, digital health will continue to thrive in coming years. In addition, disrupted clinical trials and the subsequent delay in drug launches is also expected to pave the way for entirely virtual trials in the future. New technologies such as mRNA is expected to emerge and shift the pharmaceutical industry and market is also expected to witness more vertical integration and joint ventures in coming years.
Lucrative Regions for Global Medical Foods for Inborn Errors of Metabolism Market
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Market Insights
Growing Preference toward Dietary Supplements to Drive Global Medical Foods for Inborn Errors of Metabolism Market Growth
The rates for consumption of nutraceutical supplements and prescribed medical food are increasing over enzyme-based therapeutic medicines. The increasing costs of healthcare and rising preference of consumers toward simple and effective remedies for disease management are likely to be responsible for the changing lineage from medicines toward medical supplements and nutritional foods. Medical food refers to a category of products that are used in dietary management of various diseases including inborn errors of metabolism that contains specific nutrients to fulfill the nutrient requirements for patients suffering from particular conditions.
The US Food and Drug Administration (FDA) have categorized medical food under four major categories formulas for metabolic disorders, complete nutritional products, nutritionally incomplete products, and oral rehydration solutions.
The medical foods are easy to be accessed as they do not require a prescription but are necessarily consumed under a medical supervision. In case of inborn errors of metabolism, medical foods are used as treatment options, and the products available in the market are regulated under authoritative and regulatory food and diet supplement statuses. The nutritional treatment for inborn errors of metabolism provides between 85% and 90% of nutritional requirement for a person suffering from a particular inherited disorder. Moreover, there are almost negligible side effects of these supplements, making them ideal for consumption for patients of all age groups. In recent years, the private medical insurers in the US and a few other countries are also offering reimbursement programs for the consumption of certain medical foods. Thus, the rising adoption of medical food and nutrient supplements is expected to foster the market growth over the years to come.
Product -Based Insights
In terms of product type, the global medical foods for inborn errors of metabolism market is segmented into amino acids, glytactin with GMP, amino acid-modified infant formula with iron, low calcium/vitamin-D infant formula with iron, low protein food and others. In 2019, the amino acid segment held largest share of the market. Also, the same segment is estimated to register the highest CAGR during the forecast period.
Global Medical Foods for Inborn Errors of Metabolism Market, by Product– 2019 and 2027
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Age group -Based Insights
In terms of age group, the global medical foods for inborn errors of metabolism market is segmented into infants, weaning, adolescents and adults. In 2019, the infants segment held largest share of the market. Also, the same segment is estimated to register the highest CAGR during the forecast period.
Disease -Based Insights
Based on disease, the global medical foods for inborn errors of metabolism market is segmented into phenylketonuria (PKU), maple syrup urine disease (MSUD), homocystonuria, urea cycle disorders, methylmelonic academia, organic acidureas, propionic academia, isovaleric academia, disorders of leucine metabolism, glutaric academia type-1, renal disease, tyrosinemia types I and II and others. The phenylketonuria segment held the largest market share in 2019. However, the glutaric academia type-1 segment is expected to grow at the fastest rate during the coming years.
Forms -Based Insights
Based on forms, the global medical foods for inborn errors of metabolism market is segmented into powder, liquids, gels, and others. The powder segment held the largest market share in 2019. Also, the same segment is estimated to grow at the highest CAGR during the forecast period.
Packaging-Based Insights
In terms of packaging, the global medical foods for inborn errors of metabolism market is segmented into can, jar, packet, bottle, and others. The can segment held the largest share of the market in 2019. However, the packets segment is expected to grow at the highest CAGR during the forecast period.
Distribution Channel -Based Insights
In terms of distribution channel, the global medical foods for inborn errors of metabolism market is segmented into retail pharmacies, hospital pharmacies, online pharmacies, drug stores and others. The retail pharmacies segment held the largest share of the market in 2019. Also, the same segment is estimated to grow at the fastest rate during the forecast period.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Medical Foods for Inborn Errors of Metabolism Market: Strategic Insights
Market Size Value in US$ 2,507.80 Million in 2019 Market Size Value by US$ 5,768.79 Million by 2027 Growth rate CAGR of 11.2% from 2020-2027 Forecast Period 2020-2027 Base Year 2020
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Medical Foods for Inborn Errors of Metabolism Market: Strategic Insights
| Market Size Value in | US$ 2,507.80 Million in 2019 |
| Market Size Value by | US$ 5,768.79 Million by 2027 |
| Growth rate | CAGR of 11.2% from 2020-2027 |
| Forecast Period | 2020-2027 |
| Base Year | 2020 |
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
The global medical foods for inborn errors of metabolism market players are adopting the product launch and expansion strategies to cater to changing customer demands worldwide, which also allows them to maintain their brand name globally.
Global Medical Foods for Inborn Errors of Metabolism Market – by Product
- Amino Acid
- Glytactin with GMP
- Amino Acid-Modified Infant Formula With Iron
- Low-Calcium/Vitamin D-free Infant Formula With Iron
- Low Protein Food
- Others
Global Medical Foods for Inborn Errors of Metabolism Market – by Age Group
- Infants
- Weaning
- Adolescents
- Adults
Global Medical Foods for Inborn Errors of Metabolism Market – by Disease
- Phenylketonuria(PKU)
- Maple Syrup Urine Disease(MSUD)
- Homocystinuria
- Urea Cycle Disorders
- Methylmalonic Acidemia
- Organic Acidurias
- Propionic Acidemia
- Isovaleric aciDemia
- Disorders of Leucine Metabolism
- Glutaric Acidemia Type I
- Renal Disease
- Tyrosinemia Types I and II
- Others
Global Medical Foods for Inborn Errors of Metabolism Market – by Forms
- Powder
- Liquid
- Gels
- Others
Global Medical Foods for Inborn Errors of Metabolism Market – by Packaging
- Can
- Jar
- Packets
- Bottle
- Others
Global Medical Foods for Inborn Errors of Metabolism Market – by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Drugstores
- Others
Global Medical Foods for Inborn Errors of Metabolism Market – by Geography
- North America
- US
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- UK
- Spain
- Rest of Europe
- Asia Pacific (APAC)
- China
- India
- South Korea
- Japan
- Australia
- Rest of APAC
- Middle East & Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Rest of MEA
- South America and Central America (SCAM)
- Brazil
- Argentina
- Rest of SCAM
Company Profiles
- Nestlé Health Science
- Abbott
- Reckitt Benckiser Group Plc
- Ajinomoto Cambrooke, Inc.
- Solace Nutrition
- Primus Pharmaceuticals, Inc.
- BioMarin Pharmaceutical
- Danone SA
- Galen Limited
- PKU-MDmil
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Product ; Age group ; Disease ; Forms ; Packaging ; Distribution Channel ; and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
Medical food refers to the specialized kind of food formulated to be consumed under physician supervision and intended for specific dietary management of a particular disease or condition. These medical conditions usually have distinctive nutritional requirements based on scientific and recognized principles that are established by medical evaluation. The medical food differs from drugs; however they are intended for consumption under the medical supervision as a primary intervention. When infants are identified with inborn errors of metabolism, they are usually prescribed a special diet suitable to their particular condition that must be followed for the lifetime.
Factors such as increasing incidence of inborn errors of metabolism and increasing preference towards dietary food supplements are expected to boost the growth of the global medical foods for inborn errors of metabolism market. However, the market is likely to get impacted by the limitations associated to medical foods for inborn errors of metabolism during the forecast period.
North America is the largest market for the medical foods for inborn errors of metabolism market. The factors that are responsible for the dominance of the region include rising government support well-developed healthcare facilities, presence of top market players, increasing number of patients with inborn errors of metabolism and rising awareness regarding benefits of consuming nutritional supplements under medical supervision. Similarly, in Canada, increasing government initiatives to raise awareness regarding rare genetic disorders and well-established healthcare infrastructure are leading to market growth. Asia-Pacific is anticipated to register as the fastest-growing region in the global medical foods for inborn errors of metabolism market. The growth of the market is expected to be fastest in countries such as China, India, and Japan. The factors that are expected to drive the market growth include large number of patients suffering with genetic diseases and increasing launch of innovative products by local players in the Asian countries. Increasing collaborations and partnerships are also responsible for the growth of the market in the Asian region.
The List of Companies - Medical Foods for Inborn Errors of Metabolism Market
- Nestlé Health Science
- Nutricia
- Solace Nutrition
- Abbott
- Mead Johnson and Company, LLC.
- BioMarin Pharmaceutical
- Ajinomoto Cambrooke, Inc.
- Poa Pharma
- PKU-MDmil
- Primus Pharmaceuticals, Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Medical Foods for Inborn Errors of Metabolism Market
Jun 2020
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jun 2020
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jun 2020
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jun 2020
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jun 2020
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jun 2020
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Jun 2020
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Jun 2020
Drug Delivery Market
Forecast to 2028 - Global Analysis By Route of Administration (Injectable Drug Delivery, Oral Drug Delivery, Transmucosal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, and Ocular Drug Delivery), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and End User (Hospitals and Clinics, Home Care Settings, and Other End User)